Antibodies, including single-domain antibodies, that bind to SARS-CoV2 virus and methods of treatment using single-do-main antibodies that bind to SARS-CoV2 virus are provided.

Antibodies, including single-domain antibodies, that bind to SARS-CoV2 virus and methods of treatment using single-do-main antibodies that bind to SARS-CoV2 virus are provided.

Disclosed herein are methods for the direct readout of proteoforms and complexes thereof, such as immunoglobulins. The method may comprise ionizing a sample with an ionizer, wherein the sample comprises a mixture of different proteoforms or complexes thereof; detecting a multiplicity of ions generated by the ionization of the sample with a current detector; determining ion masses for each of the multiplicity of ions detected with the current detector with a mass analyzer; generating a mass-domain spectrum from the ion masses with the mass analyzer. The method may also comprise determining one or more metrics capturing the heterogeneity or relative abundance of proteoforms.

The invention described herein provides neutralizing antibodies against SARS-CoV-2 antigens (such as the S1 subunit of the S antigen) for use in treating human patients having COVID-19.

The invention described herein provides neutralizing antibodies against SARS-CoV-2 antigens (such as the S1 subunit of the S antigen) for use in treating human patients having COVID-19.

The present invention relates to the field of virology, more specifically to the field of zoonotic Coronaviruses. Specifically, the invention provides for binding agents specific for the spike protein receptor binding domain (RBD) of the SARS-Corona virus, more specifically for an epitope of the RBD present in a broad range of Sarbecoviruses and mutants thereof, even more specifically present in SARS-Cov and SARS-CoV-2 viruses. More specifically, the invention relates to compositions comprising antibodies capable of specifically binding and neutralizing SARS-Corona viruses. More specifically the invention relates to compositions comprising single domain antibodies, or specifically VHHs, and compositions comprising multivalent binding agents comprising IgG Fc fusions thereof, specifically VHH-Fc fusions thereof, even more specifically comprising heavy chain only VHH72-S56A-IgG1-Fc fusions, or compositions comprising any humanized form of any one thereof, and are capable of specifically binding and neutralizing SARS-Corona viruses, specifically SARS-Cov-2 virus. The compositions are useful in the diagnosis of Sarbecoviruses, and specifically SARS-CoV-2 virus, and in prophylactic and/or therapeutic treatment of a condition resulting from infections with Sarbecoviruses, specifically SARS-Corona or SARS-CoV-2 virus, or mutants thereof.

The present invention relates to the field of virology, more specifically to the field of zoonotic Coronaviruses. Specifically, the invention provides for binding agents specific for the spike protein receptor binding domain (RBD) of the SARS-Corona virus, more specifically for an epitope of the RBD present in a broad range of Sarbecoviruses and mutants thereof, even more specifically present in SARS-Cov and SARS-CoV-2 viruses. More specifically, the invention relates to compositions comprising antibodies capable of specifically binding and neutralizing SARS-Corona viruses. More specifically the invention relates to compositions comprising single domain antibodies, or specifically VHHs, and compositions comprising multivalent binding agents comprising IgG Fc fusions thereof, specifically VHH-Fc fusions thereof, even more specifically comprising heavy chain only VHH72-S56A-IgG1-Fc fusions, or compositions comprising any humanized form of any one thereof, and are capable of specifically binding and neutralizing SARS-Corona viruses, specifically SARS-Cov-2 virus. The compositions are useful in the diagnosis of Sarbecoviruses, and specifically SARS-CoV-2 virus, and in prophylactic and/or therapeutic treatment of a condition resulting from infections with Sarbecoviruses, specifically SARS-Corona or SARS-CoV-2 virus, or mutants thereof.

The present invention provides a new antibody against ECSA type Chikungunya virus, WA type Chikungunya virus, and Asian type Chikungunya virus or an antigen-binding fragment of the antibody. The antibody against Chikungunya virus or the antigen-binding fragment of the antibody of the present invention includes a heavy chain variable region or a heavy chain (1), (2), or (3) and a light chain variable region or a light chain (4).

Provided herein are anti-neuraminidase agents useful for neutralization of influenza virus infection, and methods of use and manufacture thereof. In particular, compositions comprising anti-neuraminidase agents (e.g., antibodies) that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.

Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.